Last reviewed · How we verify
Biotest — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
9 Phase 3
3 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Trimodulin | Trimodulin | phase 3 | Other | |||
| Zutectra | Zutectra | phase 3 | Other | |||
| BT524 | BT524 | phase 3 | Monoclonal antibody (anti-TFPI) | Tissue Factor Pathway Inhibitor (TFPI) | Hematology | |
| BT595 | BT595 | phase 3 | Monoclonal antibody (anti-TFPI) | Tissue Factor Pathway Inhibitor (TFPI) | Hematology | |
| Placebo (human albumin 1%) | Placebo (human albumin 1%) | phase 3 | Plasma volume expander / Colloid | Critical Care / Hematology | ||
| BT524 (Part II) | BT524 (Part II) | phase 3 | Monoclonal antibody (anti-TFPI) | Tissue Factor Pathway Inhibitor (TFPI) | Hematology | |
| BT524 (Part I) | BT524 (Part I) | phase 3 | Monoclonal antibody (anti-TFPI) | Tissue Factor Pathway Inhibitor (TFPI) | Hematology | |
| IgG Next Generation (BT595) | IgG Next Generation (BT595) | phase 3 | Intravenous immunoglobulin (IVIG) | Immunology | ||
| FFP/Cryo | FFP/Cryo | phase 3 | Blood product / Hemostatic agent | Hematology / Critical Care |
Therapeutic area mix
- Hematology · 4
- Oncology · 2
- Other · 2
- Critical Care / Hematology · 1
- Hematology / Critical Care · 1
- Immunology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Baxalta now part of Shire · 2 shared drug classes
- CSL Behring · 2 shared drug classes
- Alexion Pharmaceuticals, Inc. · 1 shared drug class
- Arbeitsgemeinschaft medikamentoese Tumortherapie · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Azienda Ospedaliera Universitaria Integrata Verona · 1 shared drug class
- Amgen · 1 shared drug class
- AgeneBio · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Biotest:
Cite this brief
Drug Landscape (2026). Biotest — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biotest. Accessed 2026-05-14.